Navigation Links
RXi Pharmaceuticals to Present at the 5th Annual Cancer BioPartnering & Investment Forum
Date:3/22/2017

MARLBOROUGH, Mass., March 22, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, today announced Alexey Eliseev, PhD, RXi's Chief Business Officer, will present at the 5th Annual Cancer BioPartnering & Investment Forum. The forum will provide a platform to present to and meet with thought leaders from cancer research institutes, leading pharmaceutical and biotech companies as well as institutional investors. This event will take place at the New York Academy of Sciences in New York City, New York on March 28, 2017.  

  • March 28, 2017, Track B - 11:50am
    Alexey Eliseev, PhD, Chief Business Officer, RXi Pharmaceuticals
    Presentation ­­–Targeting Immune Checkpoints in Adoptive Cell Transfer Using Self-Delivering RNAi (sd-rxRNA®) Technology

The presentation will be available under the "Investors – Presentations & Posters" section of the Company's website, www.rxipharma.com approximately 1 hour following the presentation.

About RXi's Proprietary Self-delivering RNAi (sd-rxRNA) Technology Platform

RXi's proprietary sd-rxRNA technology has many advantages over its competitors in the RNAi space. Scientists at RXi have designed chemically-modified RNAi compounds with improved drug-like properties that are potent, stable and specific. These proprietary compounds have built-in delivery properties and therefore do not require a delivery vehicle for local therapeutic applications.  The enhanced properties of sd-rxRNA include: efficient spontaneous cellular uptake, stability, reduced potential for immune stimulation, and potent, long-lasting intracellular activity. All cell types tested (primary, neuronal and non-adherent) internalize sd-rxRNA compounds uniformly and efficiently, resulting in potent and long lasting silencing. sd-rxRNA compounds have the ability to selectively block the expression of any target in the genome, thus providing applicability to a broad spectrum of therapeutic areas.

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs. Building on the pioneering discovery of RNAi, scientists at RXi have harnessed the naturally occurring RNAi process which has the ability to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition. RXi developed a robust RNAi therapeutic platform including self-delivering RNA (sd-rxRNA®) compounds, that have the ability to highly selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas. Our current programs include dermatology, ophthalmology and cell-based immunotherapy. RXi's extensive patent portfolio provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas and we actively pursue research collaborations, partnering and out-licensing opportunities with academia and pharmaceutical companies. Additional information may be found on the Company's website, www.rxipharma.com.  

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone™ and our other product candidates (collectively "our product candidates"); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors." Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Contact

RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com

Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-the-5th-annual-cancer-biopartnering--investment-forum-300427551.html


'/>"/>
SOURCE RXi Pharmaceuticals Corporation
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Juniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results
2. Former Allergan Chief David Pyott Signs on as Special Advisor to Sienna Biopharmaceuticals
3. AcelRx Pharmaceuticals New Drug Application for DSUVIA Accepted for Filing with PDUFA Date of October 12, 2017
4. Provectus Biopharmaceuticals Provides Information On Rights Offering Deadline
5. FACIT-Seeded Fusion Pharmaceuticals Closes US$25M Series A Led by Johnson & Johnson Innovation
6. OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented at the American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
7. Vanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results
8. Innovate Biopharmaceuticals, Targeting Celiac Disease And Ulcerative Colitis, presenting at BIO CEO & Investor Conference
9. Incorporating Safety Pharmacology Endpoints in Toxicology Studies: Transposing the Experience with Biopharmaceuticals Into Small Molecules
10. CoLucid (CLCD) Alert: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of CoLucid Pharmaceuticals, Inc.; Is $46.50 a Fair Price?
11. Ionis Pharmaceuticals to Host a Pipeline Update Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... NEWTOWN SQUARE, Pa. , June 20, 2017 /PRNewswire/ ... technology, is pleased to announce the issuance of a ... treating gout or hyperuricemia by the U.S. Patent and ... Biotech Inc., a winner of the Buzz of Bio ... , is akin to developing non-drug approaches to ...
(Date:6/19/2017)... ... June 19, 2017 , ... EDETEK, Inc., a ... that it is launching two new additions of its award-winning cloud-based platform CONFORM™: ... at the DIA 2017 Annual Meeting in Chicago, IL, June 19-22, 2017. , ...
(Date:6/16/2017)... ... ... CTNext , Connecticut’s go-to resource for entrepreneurial support, today announced the ... Piers in Stamford. , Nine finalists, all of whom are Connecticut-based companies and entrepreneurs, ... secure $10,000 awards to help support business growth. The winners included:, ...
(Date:6/15/2017)... , ... June 15, 2017 , ... ... director for DuPont Biofuels, will be speaking at Bloomberg’s 2017 Sustainable Business ... join other leading environmental and sustainability officials on a panel titled “Developing a ...
Breaking Biology Technology:
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):